Drug intelligence / Profile preview

PSMA-1-IR800

Development stage
Preclinical
Lead developer
Case Western Reserve University
Modality
Small Molecules, Peptides
Administration
Intravenous
01

Overview

PSMA-1-IR800 (also known as PSMA-1-IRDye800CW) is a preclinical near-infrared (NIR) fluorescent imaging agent designed for the intraoperative visualization and fluorescence-guided surgery of prostate cancer. Developed by researchers at Case Western Reserve University and the Cleveland Clinic, the agent consists of a high-affinity, urea-based peptidomimetic ligand (PSMA-1) conjugated to the near-infrared fluorescent dye IRDye 800CW. PSMA-1-IR800 specifically targets prostate-specific membrane antigen (PSMA), a cell-surface protein highly overexpressed in prostate cancer cells and tumor neovasculature. Upon binding to PSMA, the agent enables real-time, high-contrast fluorescence imaging of tumor margins and metastatic lesions, helping surgeons achieve complete tumor resection while minimizing damage to healthy tissues. Preclinical studies in mouse models have demonstrated excellent tumor accumulation and rapid clearance from non-target tissues, with notably low uptake in salivary glands compared to other PSMA-targeted agents.

Other names
PSMA-1-IR800CWPSMA1-IR800CWPSMA 1-IR800CWPSMA-1-IRDye800PSMA1-IRDye800PSMA 1-IRDye800PSMA-1-IRDye800CWPSMA1-IRDye800CWPSMA 1-IRDye800CW
02

Identity

Drug type
Non-Radioactive Imaging and Contrast Agents
Originator
Case Western Reserve University
Modality
Small MoleculesPeptides
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
prostate cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Case Western Reserve UniversityOriginator · Lead developer
07

Patents & exclusivity

Patents
6

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
195
Drugs in the lead indication
564

Lead indication: prostate cancer and precursor lesions

Most advanced in the lead indication

  1. 18F-PSMA-11Approved
  2. flotufolastat f 18Approved
  3. gallium ga-68 gozetotideApproved
  4. piflufolastat f 18Approved
  5. aminocaproic acidApproved

Beyond the preview

Go deeper on PSMA-1-IR800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMA-1-IR800.

Work on PSMA-1-IR800? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call